Editorial: Advancing Therapeutic Strategies: Exploring ABC Transporters and Chemicals Affecting Their Expression and Function for Disease Treatment

Overview

Journal Front Pharmacol

Date 2024 May 28

PMID 38803436

Authors

Guido Veit

Michinori Matsuo

Tsukasa Okiyoneda

Affiliations

Soon will be listed here.

References

Moore J, Bell E, Hughes R, Garfield A . ABC transporters: human disease and pharmacotherapeutic potential. Trends Mol Med. 2022; 29(2):152-172. DOI: 10.1016/j.molmed.2022.11.001. View

Rehman T, Karp P, Tan P, Goodell B, Pezzulo A, Thurman A . Inflammatory cytokines TNF-α and IL-17 enhance the efficacy of cystic fibrosis transmembrane conductance regulator modulators. J Clin Invest. 2021; 131(16). PMC: 8363270. DOI: 10.1172/JCI150398. View

Gentzsch M, Cholon D, Quinney N, Martino M, Minges J, Boyles S . Airway Epithelial Inflammation Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies. Front Pharmacol. 2021; 12:628722. PMC: 8042279. DOI: 10.3389/fphar.2021.628722. View

Vauthier V, Housset C, Falguieres T . Targeted pharmacotherapies for defective ABC transporters. Biochem Pharmacol. 2017; 136:1-11. DOI: 10.1016/j.bcp.2017.02.020. View

Kinting S, Hoppner S, Schindlbeck U, Forstner M, Harfst J, Wittmann T . Functional rescue of misfolding ABCA3 mutations by small molecular correctors. Hum Mol Genet. 2018; 27(6):943-953. DOI: 10.1093/hmg/ddy011. View

Lopes-Pacheco M, Pedemonte N, Veit G . Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov. 2021; 16(8):897-913. DOI: 10.1080/17460441.2021.1912732. View

Middleton P, Mall M, Drevinek P, Lands L, McKone E, Polineni D . Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019; 381(19):1809-1819. PMC: 7282384. DOI: 10.1056/NEJMoa1908639. View

Veit G, Avramescu R, Chiang A, Houck S, Cai Z, Peters K . From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016; 27(3):424-33. PMC: 4751594. DOI: 10.1091/mbc.E14-04-0935. View

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

10.

Veit G, Vaccarin C, Lukacs G . Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. J Cyst Fibros. 2021; 20(5):895-898. PMC: 8463622. DOI: 10.1016/j.jcf.2021.03.011. View

11.

Dean M, Moitra K, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Hum Mutat. 2022; 43(9):1162-1182. PMC: 9357071. DOI: 10.1002/humu.24418. View